Interim Results

Interim Results Statement for the 6 Month Period Ended 31 December 2005

Oxford, UK 31 March 2006:  The Board of Physiomics plc (AIM:PYC), a European
systems biology simulation company, today announces the financial results for
the six months ending 31st December 2005. Physiomicsplc is a computational
systems biology services company, developing computer simulations aimed
at reducing the high cost and attrition rates of clinical trials, particularly
for cancer therapies.

Highlights of the period

Turnover of £91,000

Losses after tax of £188,000, a reduction of 20% over the comparable period

Cash at 31st December was £137,000

Significant technical progress made in developing virtual tumour models

Appointment of Mr David Evans as Chairman

Mr David Evans, Chairman of Physiomics commented:

Turnover for the six month period was £91,000 (2004: £96,000). The operating
loss for the period was reduced to £188,000 (2004: £236,000) and the loss both
before and after taxation was £184,000 (2004: £236,000). The loss per Ordinary
Share was 0.08 p (2004: 0.13p).

The cash position on 31st December was £137,000 (£437,000 in December 2004
immediately post IPO and £294,908 as of 30th June 2005 ).  The Company is
negotiating with both Billam plc and Billam AG funding to enable the
Board to continue to develop the business both organically and via potential
external opportunities identified through a strategic review process. These
funding arrangements will replace the Put and Call Option based financing
arrangements put in place at time of flotation. This funding started in March
2006, although legal documents have still to be finalised.

The Company maintains an active dialog with a variety of major pharmaceutical
and leading biotechnology companies about fee-for-service consultancy.  In an
extension of its business activities, the company is also exploring options to
partner with or acquire cancer projects.

In this area, the integrated systems approach developed with Bayer Technology
Services GmbH can deliver added value to drug development. Some 25% of all
pharmaceutical projects entering the clinic are cancer related yet 95% of these
fail to complete development. The revaluation and revitalisation
of projects offers a major commercial opportunity for the integrated technologies
and services being developed by Physiomics.

As part of the marketing process, Physiomics obtained a trade mark for its
SystemCell®softwareand applied for a trademark on Clinicophore®as a brand for
integrated systems biology services targeted at clinical development. This
trademark was subsequently granted in February 2006. The Company's website was
also redesigned to provide a more informed interface for investors, customers
and to promote the Company's public image .

Physiomics operates in the area of systems biology which is a technically
demanding and research intensive new area of post-genomic science. On 25th
October the Company announced the achievement of an important technical
mile stone in developing a sophisticated addition to its core cell growth model.

The technical innovation shows, using Physiomics' SystemCell® software, complex
virtual cells "growing" in the computer to mimic the experimental behaviour of
many cancer cells and their responses to drugs. This important development
paves the way for realistic and predictive models of tumour drug
responses. After the year end, Physiomics filed a patent to protect this
invention.

Outlook

The interim financing made available to the Company by Billam plc and Billam AG
is very welcome but the Board needs to secure a long term future for the
Company on a basis different from the current business model which is
generating insufficient revenues for its overhead base.

Whilst the Board has evaluated a number of opportunities the ability to pursue
these to a conclusion is wholly dependent upon shareholder support and allied
future fund-raising. This by definition has a limiting effect on the
opportunities that are likely to gain shareholders' support given the
continuing 75% EiRx Pharma Ltd shareholding .


Physiomics Plc                                                                         
                                                                                       
Unaudited Profit and Loss Account for the six months ended 31 December 2005            
                                                                                       
                                                  6 mos to    6 mos to     12 mos to   
                                                                                       
                                                 31.12.2005  31.12.2004    30.6.2005   
                                                                                       
                                                                           (audited)   
                                                                                       
                                                   £ 000       £ 000         £ 000     
                                                                                       
Turnover                                             91          96           205      
                                                                                       
Operating loss                                     (188)       (236)         (440)     
                                                                                       
Loss on ordinary activities before finance costs   (188)       (236)         (440)     
                                                                                       
Net finance income                                   4           -             9       
                                                                                       
Loss on ordinary activities before taxation        (184)       (236)         (432)     
                                                                                       
Taxation                                             -           -             50      
                                                                                       
Loss on ordinary activities after taxation         (184)       (236)         (382)     
                                                                                       
Dividends                                            -           -             -       
                                                                                       
Retained loss                                      (184)       (236)         (382)     
                                                                                       
Earnings (loss) per share in pence                 (0.08)      (0.13)        (0.19)    
                                                                                       
Copies of these interim statements will be posted to shareholders in due course        
and are                                                                                
                                                                                       
available from the company's offices at The Magdalen Centre, Robert Robinson           
Avenue,Oxford Science Park, Oxford OX4 4GA.                                                   
                                                                                       


Physiomics Plc                                                           
                                                                         
Unaudited Balance Sheet as at 31 December 2005                           
                                                                         
                                       31.12.05   31.12.04     30.06.05  
                                                                         
                                                              (audited)  
                                                                         
                                        £ 000      £ 000        £ 000    
                                                                         
Fixed assets                                                             
                                                                         
Tangible fixed assets                     19         12           25     
                                                                         
Intangible fixed assets                   51         56           53     
                                                                         
Current assets                                                           
                                                                         
Debtors                                   78        384          154     
                                                                         
Cash at bank                             137        437          295     
                                                                         
                                         215        821          449     
                                                                         
Current liabilities                                                      
                                                                         
Creditors falling due within one year    (56)      (349)        (114)    
                                                                         
Net current assets/(liabilities)         159        472          335     
                                                                         
Net assets/(liabilities)                 229        540          413     
                                                                         
Capital and reserves                                                     
                                                                         
Called up share capital                   93         92           93     
                                                                         
Share premium account                   1,329      1,310        1,329    
                                                                         
Profit and loss account                (1,193)     (862)       (1,009)   
                                                                         
Total shareholders' funds/(deficit)      229        540          413     
                                                                         

Physiomics Plc                                                                               
                                                                                             
Unaudited Cash Flow Statement for the six months ended 31 December 2005                      
                                                                                             
                                                          31.12.05         31.12.04  31.12.03
                                                                                             
                                                            £ 000           £ 000     £ 000  
                                                                                             
Cash outflow from operating activities                      (198)           (700)      (5)   
                                                                                             
Return on investments and servicing of finance                                               
                                                                                             
Interest received                                             4                              
                                                                                             
Taxation                                                     36               -         -    
                                                                                             
Purchase of tangible fixed assets                            (0)             (1)        -    
                                                                                             
Management of liquid resources                                                               
                                                                                             
Cash held on short term deposit                               -             (400)       -    
                                                                                             
Cash outflow before financing                               (158)          (1,101)     (5)   
                                                                                             
Financing                                                                                    
                                                                                             
Net proceeds of IPO                                           -             1,129       -    
                                                                                             
Increase/(decrease) in cash in the period                   (158)             28       (5)   
                                                                                             

                                   - ENDS -                                    


Notes to Editors

Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials.  As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates show that an overall ten per
cent. improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around
$800 million. 

Physiomics is currently focused on optimising the design of cancer clinical
trials as a service to major pharmaceutical companies. In addition, it has
secured an option to in-license two innovative molecules in the cancer area
from Cronos Therapeutics.  Physiomics has a major collaboration with Bayer
Technology Services GmbH to develop globally clinical response prediction
services using both companies' proprietary technologies and mathematical cell
models, including the SystemCell® technology developed by Physiomics. In June
2005, Physiomics became a distributor of Bayer's PK-Sim® product for
understanding the way pharmaceuticals are distributed round the body.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. 

For further information, please visit www.physiomics-plc.com 

SystemCell and Clinicophore a re registered trademark s of Physiomics plc .

For further information please contact:

Physiomics plc                                                             
Tel:+ 44 1865 784 980

Mr David Evans(Chairman)                                           

Dr John Savin (CEO)

Northbank Communications                                          
Tel: + 44 207 886 8150  

City/Financial Enquiries 

Emma Palmer,                                                              

Scientific/Trade P ress Enquiries                                            

Fiona Brown /

Rowan Minnion